Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.
about
A review of malaria vaccine clinical projects based on the WHO rainbow tableDisruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasitesInsights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical MalariaParasite Carbohydrate Vaccines.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens.The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.Spatial variation in genetic diversity and natural selection on the thrombospondin-related adhesive protein locus of Plasmodium vivax (PvTRAP).Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda.Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigensAntibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemicA phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of ageMeasuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens.Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adultsAnalysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX™).Holoendemic malaria exposure is associated with altered Epstein-Barr virus-specific CD8(+) T-cell differentiation.Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.High levels of antibodies to Plasmodium falciparum liver stage antigen-1 in naturally infected individuals in MyanmarCommunity-wide Prevalence of Malaria Parasitemia in HIV-Infected and Uninfected Populations in a High-Transmission Setting in Uganda.Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria.Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.Antigens for pre-erythrocytic malaria vaccines: building on success.Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants.Cell biology and immunology of malaria.Naturally acquired antibody response to Plasmodium falciparum describes heterogeneity in transmission on islands in Lake Victoria.Immune Responses in Malaria.Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study.[Profiles of IgG responses against CSP, GLURP and LSA-3NR2 in urban malaria (Dakar): relations with haemoglobin levels and parasite densities].Synthetic Antigens Derived from Plasmodium falciparum Sporozoite, Liver, and Blood Stages: Naturally Acquired Immune Response and Human Leukocyte Antigen Associations in Individuals Living in a Brazilian Endemic Area.Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya.Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children.
P2860
Q21034112-BA0FF1E9-B24E-44FD-B923-0014B30673FCQ27974558-FC0EA964-0E09-4864-B7B1-626EE211CAFDQ33430011-7968A2FE-087B-43A8-8B12-AECC0839EBE2Q33577093-05E72AF4-4761-4F6B-923C-816B65E6CFEEQ33646573-3C17C36C-8151-42F7-99A0-13BABBEC49B2Q33785863-26254F07-0C72-42E6-9109-96A6CA5A5147Q33855899-761A3879-A351-47DB-8E4A-7196C47FADBCQ34170122-F2F0086A-EA05-4CA4-98A8-8D67BD45ABC1Q34209043-9447B9D5-2105-4254-8AA2-D8750EB9CED3Q34289823-8E328E95-E0BF-4D87-A02D-C7C6448B3DBBQ34379539-228BF3E5-1DD0-4C03-B7AC-FCEAC8482F9DQ34534163-E0B3377A-3B85-43AB-B9F6-9F693105A380Q34778078-56E20185-E168-42BB-81BD-C5BF89C06047Q35016677-72709916-85D2-4AC1-ABB3-1531BA33FAC9Q35045424-C4930802-12B2-4B7D-9420-CCFF587CC12CQ35093445-FBBC14F8-AD50-4ED1-BA06-35D0EFE9D13FQ35264640-8FA685FD-B323-49A6-A9AF-98F21860FF00Q35569042-CF0BF346-20AD-4986-B868-133F15820EFBQ36123104-C872EB49-3DFC-47DC-A542-913A84CEFE13Q36393772-1A4FD160-81A3-4C1B-A372-D156CB0386BEQ36559910-EFDDF892-EFCE-4D14-8DAA-508F9B9C6C89Q36882512-AAA8C566-5A8B-4943-96C3-2A1D6BAECDC8Q36908779-DCCDC259-51BF-4F5F-B58B-346381EC34F8Q36931785-3BBC47FC-CFE1-4FA4-ACAE-44F6A37C703FQ36953171-1CBD9D0B-3A1E-490D-B771-409C9EADC36DQ36974401-DA00F3C1-0434-44AA-B3D2-5B28B379BAB6Q37148056-28FFFD16-378F-40D3-9C8F-08FE82DEE48EQ37461371-B39A5AF6-DC73-464D-901D-4033E46CEBD0Q37582431-AF954826-BD6F-42E6-927C-45B021B3004DQ37627098-EBDC312E-37DA-43A5-A9D0-57AFDD5AB6FEQ37846879-B03D40BD-B3A2-4B1A-B924-914031BFEEF5Q38613292-D03AD8B8-56D4-48A3-8A31-F04822D66F5FQ40259888-FC3C07D8-D4A6-4827-9926-2CF973766E25Q41995596-CB753EF2-842E-4978-9488-4061AF703B86Q46299460-9D9CACED-1B4C-4C2B-909F-31E74A8DBFC5Q46758381-41717868-E9C3-4C29-8370-8C1B2F514906Q47099079-C8B04179-21B1-4FF6-B983-6CF1FCF915ABQ47341472-3FD965F2-E2E2-42B0-8F1D-9701AB84E389Q51648048-F45E6732-0EB0-4501-ABF7-7BA8AB0C6B25Q52715900-7E1084FF-CDB2-46EE-930A-DA85756111EA
P2860
Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@en
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@nl
type
label
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@en
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@nl
prefLabel
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@en
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@nl
P2093
P2860
P921
P356
P1476
Antibodies to pre-erythrocytic ...... al malaria in Kenyan children.
@en
P2093
Aaron J Tande
Ann M Moormann
David E Lanar
Peter O Sumba
Xinan M Min
P2860
P304
P356
10.1086/526787
P407
P577
2008-02-01T00:00:00Z